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Abstract
Objective: To identify potentially actionable dosimetric predictors of local control (LC) for non-
small cell lung cancer (NSCLC) brain metastases treated with single-fraction stereotactic radiosurgery
(SRS).
Methods and materials: Patients with NSCLC brain metastases treated with single-fraction SRS
were identified. Eligible patients had at least 1 follow-up magnetic resonance imaging scan and
were without prior metastasectomy or SRS to the same lesion. LC and overall survival (OS) were
estimated using the Kaplan-Meier method. The Cox proportional hazards model was used for uni-
variate (UVA) and multivariate analysis (MVA). Receiver operating characteristic (ROC) analysis
was used to identify optimal cut points for dose-volume histogram metrics relative to LC.
Results: A total of 612 NSCLC brain metastasis were identified in 299 patients with single-fraction
SRS between 1999 and 2014. Median follow-up was 10 months. Median OS from time of SRS was 11
months. Overall LC was 75% and 66% at 1 and 2 years, respectively. On UVA, increasing dose by any
measure was associated with improved LC. On MVA, volume receiving at least 32 Gy (V32; hazard
ratio [HR], 0.069; P < .000), along with higher prescription isodose (HR, 0.953; P = .031) and lower
volume (HR, 1.359; P < .000), were independent predictors of improved LC. ROC analysis demon-
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strated a V32 of 24% to be most predictive for LC. For the entire cohort, 1-year LC for V32 ≥24% was
89% versus 67% for V32 <24% (P = .000). Stratifying by volume, lesions ≤2 cm (n = 323) had a 1-year
LC of 95% versus 82% (P = .005) for V32 above and below 24%, respectively. For lesions 2.1 to 3 cm
(n = 211), 1-year LC was 79% versus 59% (P = .003) for V32 above and below 24%, respectively. Total
tumor volume alone was predictive for OS.
Conclusions: Volume, prescription isodose line, and V32 are independent predictors of LC. V32
represents an actionable SRS treatment planning parameter for NSCLC brain metastases.
© 2017 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Lung cancer is the leading cause of cancer-related death1
and the most common source of brain metastases in the United
States.2 Approximately 40% of patients diagnosed with
non-small cell lung cancer (NSCLC) develop brain metasta-
sis, with the central nervous system being the first site of failure
in 34% of patients.3 Despite treatment, brain metastases remain
the cause of mortality in 23% to 44% of patients.4
Local control (LC) of brain metastasis remains an im-
portant clinical end point. Brain metastasis control has been
correlated with improved neurocognition at 3 months5; this
has, in turn, been associated with improved quality of life.6
LC has also been associated with improved overall sur-
vival (OS).7
Actionable parameters predictive of LC have not been well
studied in stereotactic radiosurgery (SRS), however. Several
investigators have reported a positively correlated dose-LC
relationship7,8; however, prescription dose escalation is asso-
ciated with increased treatment morbidity.9 The use of whole
brain radiation therapy (WBRT) before SRS has also been as-
sociated with increased LC,10 but, as demonstrated by Chang
et al, it is also associated with a significant detriment in
neurocognition. Last, the use of an additional margin on the
gross tumor volume has been associated with improved LC;
however, the use of an additional margin is only applicable
to small metastasis in locations distant from critical struc-
tures. Because of these factors, it is clear that other actionable
parameters are needed. At present, the examination of dose-
volume histogram (DVH) metrics as they relate to LC has not
yet been described in the brain metastases SRS literature. The
primary end point of this study was assessment of action-
able DVH metrics predictive of LC that may be modified at
the time of treatment planning. Secondary outcomes include
patient-, tumor-, and treatment-related characteristics that are
predictive of LC and OS.
Methods and materials
Data collection
Patients treated at Barnes Jewish Hospital and
Washington University in St. Louis with pathologically con-
firmed NSCLC brain metastasis who received Gamma Knife
SRS between June 1999 and January 2014 were identi-
fied from an institutional review board–approved registry.
Eligible patients included those who underwent single-
fraction SRS and had at least 1 follow-up brain magnetic
resonance imaging (MRI) scan. Those who had brain-
stem metastases, radiosurgical boost to a metastasectomy
cavity, or repeat SRS to a previously treated lesion were
excluded. A total of 612 brain metastases in 299 patients
met eligibility criteria and were included for analysis. Base-
line patient, tumor, and treatment data were collected from
the medical record in retrospective fashion.
Radiosurgery
All patients underwent single-fraction SRS with the Leksell
Gamma Knife (ElektaAB, Stockholm, Sweden). Patients were
treated using Model B, C, and Perfexion from June 1999 to
August 2002, August 2002 to April 2008, and April 2008 to
the present, respectively. All patients had intravenous access
placed. The Leksell stereotactic frame was placed under local
anesthetic to the pin sites, in combination with a low-dose
anxiolytic. High-resolution contrast-enhanced MRI and
noncontrast computed tomography imaging were obtained.
Target volume delineation and treatment planning were per-
formed in concert by a medical physicist, neurosurgeon, and
radiation oncologist. The target volume was defined as the
contrast-enhancing tumor on the T1-weighted MRI images
without additional margin. Prescription dose was based gen-
erally on recommendations from Radiation Therapy Oncology
Group (RTOG) 90-05 with frequent adjustments made at the
discretion of the treating physician. Generally, lesions >3 cm
were treated to 15 Gy, lesions 2.1 to 3 cm were treated to 18 Gy,
and those ≤2 cm were treated to 20 to 24 Gy. Treatment plan-
ning parameters included tumor coverage by the prescription
isodose line while attempting to maintain a gradient index (50%
of prescription isodose volume/prescription isodose volume) < 3
and a conformality index (prescription isodose volume/
tumor volume) < 2. No specific evaluation or optimization of
the treatment plan was performed beyond these planning
parameters.
Patient follow-up
Patients underwent a brain MRI scan every 2 to 3 months
in follow-up. All brain MRI scans were reviewed from the
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time of SRS until death or last follow-up. Local failure was
assessed in each treated lesion and was defined as an in-
crease in the size of the treated metastasis at any time after
SRS unless additional imaging studies or pathology from
subsequent surgical resection suggested radiation necro-
sis. Radiation necrosis was assessed in each treated lesion
and recorded if documented by any treating physician, ra-
diologist, or pathologist.
Statistical analysis
Times were measured from the date of SRS. Clinical
characteristics between groups were compared using the
Mann-Whitney U test. DVH per lesion were manually ex-
ported from the treatment planning software (Leksell
GammaPlan 10.1 Elekta, Stockholm, Sweden) and ana-
lyzed using a custom in-house DVH tool. DVH parameters
extracted from each lesion included tumor volume in mm3,
conformality index, minimum dose to xx% (Dxx) of the
tumor volume (D10, D50, D90), minimum dose (Dmin),
maximum dose, mean dose, median dose, and the percent
of the tumor volume receiving at least xx Gy (Vxx) in 1-Gy
increments from 20 to 40 Gy. Kaplan-Meier method was
used to estimate LC and OS. Differences in LC and OS
were analyzed with the log-rank test. Univariate and mul-
tivariate analysis was performed using the Cox proportional
hazards model. For multivariate analysis, only variables sig-
nificant on univariate analysis were included in the Cox
proportional hazards model. Optimal cut points were de-
termined using a combination of graphic diagnostic plots,
a minimum P value approach, and receiver operating char-
acteristic (ROC) curves. P < .05 was considered significant.
All tests were 2-tailed. Statistical analyses were per-
formed using SAS (version 9.2; SAS Institute, Cary, NC)
and SPSS (version 21.0; IBM, Armonk, NY).
Results
Patient and treatment characteristics
Patient- and tumor-related characteristics are summa-
rized in Table 1. The median age at the time of treatment
was 61 years (range, 37-85), 55% were female, and the ma-
jority were white (86%). The majority of patients were
recursive partitioning analysis class II (63%) and the median
diagnosis specific graded prognostic assessment was 2. Two
hundred patients had control of their primary disease at the
time of radiosurgery. Most patients had adenocarcinoma
(64%). Of those with adenocarcinoma, 5% were epider-
mal growth factor receptor-positive and <1% EML4-
ALK were positive. All patients who were epidermal growth
factor receptor or EML4-ALK were on targeted agents
within 30 days of radiosurgery. Most patients had supra-
tentorial tumors (78%). The median number of brain
metastases was 1 (range, 1-8; mean, 1.7). A total of 68%
(204) patients did not receive WBRT before SRS. Treatment-
related characteristics are presented in Table 2. The median
size of brain metastases was 431 mm3, with a median dose
of 20 Gy and a median conformality index of 1.69.
Outcomes
Median follow-up was 10 months. Median OS for all
patients was 11 months, and the estimated survival at 1 and
Table 1 Patient- and tumor-related characteristics
Characteristic Value
Age (y)
Median (range) 61 (37-85)
Histology (n = 299)
Adenocarcinoma 191 (64%)
EGFR mutant 14 (5%)
EML4-ALK translocation 1 (<1%)
Squamous cell carcinoma 40 (13%)








African American 38 (13%)
Other 4 (1%)











GPA score at time of radiosurgery
Median (range) 2 (0-4)
Control of primary disease
Yes 200
No 99
Number of brain metastases at time of radiosurgery







EGFR, epidermal growth factor receptor; GPA, graded prognostic as-
sessment; KPS, Karnofsky Performance Scale; NSCLC-NOS, non-
small cell lung cancer, not otherwise specified; RPA, recursive
partitioning analysis; WBRT, whole brain radiation therapy.
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2 years was 52% and 29%, respectively. Of 612 brain me-
tastases, 123 (20%) were local failures. Overall LC was 75%
and 66% at 1 and 2 years, respectively. Multiple follow-
up MRI scans were obtained in 211 patients (71%). Failure
was assigned to 16 metastases on the basis of a single follow-
up MRI scan. There were 33 cases of radiation necrosis
(5%) in 25 patients. With regard to salvage, 16 patients un-
derwent surgical salvage after SRS, 52 patients underwent
repeat SRS for new distant brain metastasis, and 55 pa-
tients received WBRT after SRS. Of those that received
WBRT after SRS, the median time to WBRT was 6 months.
Factors associated with LC on univariate analysis are sum-
marized in Table 3. Improved LC was noted with use of
the Perfexion model, prior WBRT, smaller tumor volume,
larger (worse) conformality index, number of shots, and es-
sentially every measure of dose to tumor. Specific to the
DVH analysis, every measure from V20 to 40 Gy was sig-
nificantly correlated with LC.
On multivariate analysis (Table 4), only prescription
isodose (hazard ratio [HR], 0.953; P = .031), volume (HR,
1.359; P < .000), and V32 Gy (HR, 0.069; P < .000) re-
mained significant predictors of LC. In the multivariate
model building, it is notable that V22 to V39 remained
within the model until V32 was entered. V32 was chosen
by the model by virtue of it having the lowest P value
(P = .0004). After entry of V32 into the model, all remain-
ing Vxx were no longer significant. Prescription dose was
not significant on multivariate analysis.
ROC analysis was performed for V32 Gy, which dem-
onstrated that the most predictive cut point was 24% for
LC, although 5% to 63% were statistically significant.
Overall, the LC rate for V32 ≥24% was 89% and 67% for
V32 <24% at 1 year (Fig 1A). ROC analysis was not per-
formed for volume. Instead, volume was stratified into 3
Table 2 Treatment-related characteristics
Characteristic Value
Brain metastasis volume (mm3)
Median (range) 499 (3-21,400)
Interquartile range 96-1815
Total volume of brain metastases (mm3)
Median (range) 1930 (11-38,113)
Interquartile range 649-4820
Prescription dose (Gy)
Median (range) 20 (12-24)
Interquartile range 18-21
Prescription isodose line (%)
Median (range) 50 (45-90)
Interquartile range 50-53
Shots per lesion





Table 3 Complete list of univariate analysis of characteris-
tics potentially predicting local control
Characteristic HR 95% CI P
Age 1.01 0.988-1.027 .452
Female 0.71 0.492-1.016 .061
African American 1.00 0.582-1.721 .998
Asian 0.73 0.180-2.970 .662
RPA class II 0.92 0.634-1.342 .675
RPA class III 1.12 0.478-2.634 .791
GPA 1.03 0.817-1.295 .809
SIR class 1.06 0.936-1.193 .372
Prior WBRT 1.90 1.33-2.717 <.001
WBRT within 2 months 1.87 1.03-3.407 .039
Histology 1.40 0.874-2.240 .162
Tumor location 1.42 0.938-2.141 .097
Tumor volume (mm3) 1.57 1.40-1.759 <.001
Model C 0.65 0.369-1.15 .142
Perfexion model 0.59 0.357-0.985 .043
Dose (Gy) 0.81 0.74-0.883 <.001
Isodose 0.93 0.896-0.974 .001
Number of shots 1.12 1.08-1.151 <.001
Conformality index 0.75 0.611-0.913 .004
Gradient index 0.88 0.672-1.159 .368
Dmean 1.00 0.998-0.999 <.001
Dmedian 1.00 0.998-0.999 <.001
Dmin 1.00 0.998-0.999 <.001
D10 1.00 0.999-1.00 <.001
D50 1.00 0.998-0.999 <.001
D90 1.00 0.997-0.999 <.001
V15 0.55 0.000-798.9 .872
V18 0.04 0.007-0.255 <.001
V20 0.11 0.04-0.301 <.001
V21 0.16 0.07-0.330 <.001
V22 0.20 0.107-0.355 <.001
V23 0.19 0.107-0.321 <.001
V24 0.19 0.108-0.321 <.001
V25 0.19 0.107-0.322 <.001
V26 0.19 0.106-0.329 <.001
V27 0.17 0.092-0.310 <.001
V28 0.16 0.084-0.310 <.001
V29 0.14 0.068-0.291 <.001
V30 0.13 0.055-0.280 <.001
V31 0.09 0.035-0.229 <.001
V32 0.06 0.018-0.175 <.001
V33 0.03 0.008-0.135 <.001
V34 0.02 0.003-0.105 <.001
V35 0.01 0.001-0.075 <.001
V36 0.00 0.000-0.064 <.001
V37 0.00 0.000-0.042 <.001
V38 0.00 0.000-0.020 .001
V39 0.00 0.000-0.009 .007
V40 0.00 0.000-0.011 .235
V50 0.00 0.000-0 .983
CI, confidence interval; conformality index, prescription isodose
volume/tumor volume; D(xx), minimum dose to xx% of the tumor
volume; HR, hazard ratio; V(xx), percentage of tumor volume re-
ceiving xx Gy; SIR, score index for radiosurgery class; WBRT, whole
brain radiation therapy. Other abbreviations as in Table 1.
Bold text indicates statistical significance.
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clinically meaningful maximal axial dimension equivalent
(diameter = 2 × cuberoot (3V/4π) size categories: 3cm. The
1-year LC was 88%, 64%, and 53% for lesions less than
2cm, 2.1 to 3cm, and greater than 3cm, respectively. For
lesions ≤2 cm (n = 323), 1-year LC for V32 ≥24% versus
V32 <24% was 79% versus 59% (P = .003), respectively
(Fig 1C). For lesions >3 cm (n = 73), 1-year LC for V32
≥24% versus V32 <24% was 85% versus 47% (P = .253),
respectively (Fig 1D). The overall rate of radiation necro-
sis was 5%, with no indication of higher rates in the higher
V32 group (3 cases [0.4%] for V32 ≥24% versus 30 cases
[4.9%] for V32 <24%). Additional analysis did not reveal
V32 to be a significant predictor of radiation necrosis;
however, given the small number of cases of V32 ≥24%,
it is difficult to derive clinically meaningful conclusions on
the incidence of radiation necrosis. Univariate analysis
demonstrated that prior WBRT, age, dose, maximum dose,
graded prognostic assessment, volume of the largest brain
metastasis, number of brain metastases, and total brain me-
tastasis volume were predictive of OS; however, on
multivariate analysis, only total brain metastasis volume re-
mained significant (HR 1.76; P < .001) (Table 5).
Discussion
We report the results of a large population of patients
with NSCLC brain metastasis treated with single-fraction
SRS. In general, these patients had a limited burden of in-
tracranial disease, good performance status, and preferential
prognostic assessment scores. In examining determinants
of LC, we found that decreasing tumor volume, higher
Table 4 Candidate variables significant on univariate and multivariate analyses of characteristics predicting local control
Characteristic Univariate Multivariate
HR 95% CI P HR 95% CI P
Isodose 0.93 0.896-0.974 .001 0.953 0.911-0.996 .031
Tumor volume (mm3) 1.57 1.40-1.759 <.001 1.359 1.197-1.543 <.001
V32 0.06 0.018-0.175 <.001 0.069 0.018-0.264 <.001
Prior WBRT 1.90 1.33-2.717 <.001
WBRT within 2 months 1.87 1.03-3.407 .039
Perfexion model 0.59 0.357-0.985 .043
Dose (Gy) 0.81 0.74-0.883 <.001
Number of shots 1.12 1.08-1.151 <.001
CI 0.75 0.611-0.913 .004
Dmean 1.00 0.998-0.999 <.001
Dmedian 1.00 0.998-0.999 <.001
Dmin 1.00 0.998-0.999 <.001
D10 1.00 0.999-1.00 <.001
D50 1.00 0.998-0.999 <.001
D90 1.00 0.997-0.999 <.001
V18 0.04 0.007-0.255 <.001
V20 0.11 0.04-0.301 <.001
V21 0.16 0.07-0.330 <.001
V22 0.20 0.107-0.355 <.001
V23 0.19 0.107-0.321 <.001
V24 0.19 0.108-0.321 <.001
V25 0.19 0.107-0.322 <.001
V26 0.19 0.106-0.329 <.001
V27 0.17 0.092-0.310 <.001
V28 0.16 0.084-0.310 <.001
V29 0.14 0.068-0.291 <.001
V30 0.13 0.055-0.280 <.001
V31 0.09 0.035-0.229 <.001
V33 0.03 0.008-0.135 <.001
V34 0.02 0.003-0.105 <.001
V35 0.01 0.001-0.075 <.001
V36 0.00 0.000-0.064 <.001
V37 0.00 0.000-0.042 <.001
V38 0.00 0.000-0.020 .001
V39 0.00 0.000-0.009 .007
Abbreviations as in Tables 1 and 3.
Bold text indicates statistical significance.
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prescription isodose, and higher V32 were independent pre-
dictors of LC on multivariate analysis. Prescription to a
higher isodose line was found to be associated with im-
proved LC. The most obvious explanation is that very small
lesions are often treated to a higher prescription isodose
line because of excessive coverage at the standard 50%
isodose level; however, higher prescription isodose line re-
mained a significant predictor for LC even after accounting
for volume in multivariate analysis. The most predictive
cutpoint was 57%, although 58% to 60% were significant
as well. These results are in concordance with those found
by Sheehan et al,11 who analyzed 627 NSCLC metastases
in 273 patients treated with SRS. With respect to local
failure, they found that lower prescription isodose was a
significant predictor of failure; however, the clinical ex-
planation for such a phenomenon is not clear and may relate
to difficult to characterize idiosyncratic differences in plan-
ning for more irregularly shaped tumors that necessitate
Figure 1 Kaplan-Meier curves of local control. (A) V32 overall, (B) V32 for lesions <2 cm, (C) V32 for lesions 2.1 to 3 cm, and (D)
V32 for lesions >3 cm. V32, volume of tumor receiving at least 32 Gy.
Table 5 Candidate variables significant on univariate and multivariate analyses of characteristics predicting overall survival
Characteristic Univariate Multivariate
HR 95% CI P HR 95% CI P
Prior WBRT 1.41 1.06-1.86 .018
Age 0.98 0.966-0.955 .013
Dose 0.90 0.843-0.960 .002
Maximum dose 0.99 0.9995-0.9997 .029
GPA 0.79 0.659-0.969 .023
Number of metastases 1.12 1.01-1.25 .033
Total metastases volume (mm3) 1.00 1.00001-1.00006 .003 1.76 1.38-2.25 <.001
Largest lesion volume 1.00 1.00001-1.00006 .019
Abbreviations as in Tables 1 and 3.
Bold text indicates statistical significance.
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lower isodose line prescriptions for a given volume. In con-
trast to our findings, Shiue et al12 analyzed 496 brain
metastases and found that prescription isodose line selec-
tion was not predictive of local failure. Of the covariates
associated with LC, isodose was the least significantly cor-
related in our analysis and does not appear to have sound
clinical rationale for manipulation in an effort to improve
LC.
We also found that increasing brain metastasis volume
is a risk factor for local failure. Such a phenomenon has
been well described.3,5,9,11,13 RTOG protocol 90-05 estab-
lished current single-fraction SRS prescription maximum
tolerated dose guidelines based on tumor volume. In these
guidelines, brain metastasis volume and maximum toler-
ated dose are inversely related because dose escalation in
larger tumors was associated with increasing acute and
chronic central nervous system toxicities. As such, it is not
surprising that larger brain metastases have poor LC. To
date, there has been no clear way to alter the SRS plan in
a manner to safely improve LC while still respecting the
need to paradoxically deliver smaller prescription doses as
tumor volume increases.
Most notably, we found that doses in excess of pre-
scription dose were highly predictive of LC, even after
accounting for tumor volume and prescription dose. In fact,
prescription dose was not significantly associated with LC
in the final multivariate model. Although V32 was se-
lected by the multivariate model, this was done purely
through selection of the variable with the lowest P value,
which by definition also comes at the expense of exclud-
ing other Vxx values. In fact, before selection of V32, all
of the values ranging from V31-V35 had a P value <.001.
Thus, the ultimate metric used to evaluate hotspots is less
important than the phenomenon being described; that is,
idiosyncratic differences in radiation planning leading to
larger hotspots (“internal dose escalation”) within the target,
even for a given prescription dose and volume of tumor,
are associated with improved LC. Moreover, this increase
in LC is not associated with a clear increase in radiation
necrosis.
The underlying reason why larger hotspots increased LC
is not well understood. It is possible that this observation
is due to the underlying nature of Gamma Knife SRS treat-
ment planning, in that the dosimetry is inherently
inhomogeneous. It is possible areas of internal dose esca-
lation lead to increased dose to high-risk, more radioresistant
volumes within the tumor, such as the hypoxic subvolume.
Interestingly, this was the hypothesized explanation for the
decrease in local progression with Gamma Knife radio-
surgery in RTOG 90-05. A similar theory has been postulated
by Tome et al,14 who reported that boosting of a tumor
subvolume has the potential to yield an increase in tumor
control probability (TCP). They noted, however, that to
achieve an increase in TCP a significant portion of the tumor
(60%-80%) must be boosted. When specifically model-
ing hypoxic subvolumes, Popple et al15 noted that boosting
modest volumes of geometrically stable hypoxia leads to
significant increases in TCP. They noted that boost doses
of 120% to 150% of the primary dose to hypoxic subvolume
increased TCP to that found in the absence of permanent
hypoxia. Building on these theories, Kim et al16 per-
formed a prostate cancer planning study evaluating the use
of selective high-risk subvolume boosting intensity modu-
lated radiation therapy (IMRT) against that of homogenous
dose escalation IMRT for plans delivering the same equiva-
lent uniform dose. They demonstrated that selective high-
risk area boosting IMRT increased the TCP without
significant dose increases to surrounding normal struc-
tures as compared with dose-escalated IMRT. Similarly,
using positron emission tomography (PET) imaging,
Vanderstaeten et al17 performed a study in head and neck
cancer comparing PET contour-based IMRT to that of PET
voxel intensity-based IMRT. Using PET voxel-based in-
tensity maps allows for dose escalation within the most
radioresistant regions of the tumor. The planning study dem-
onstrated that PET voxel intensity-based IMRT has the
potential to improve LC without increasing toxicity to sur-
rounding organs. Our findings require validation against
underlying imaging data to examine whether there is a cor-
relation between radioresistant subvolumes and that of
internal dose escalation.
The principal limitation of our work is its single-
institution, retrospective design; furthermore, our definition
of LC may over-report failures. Last, at present, we have
not yet explored the correlation between internal dose es-
calation and underlying radiomics, which may further
explain our findings. Despite these limitations, however, we
have identified specific factors correlated with individual
tumor LC after SRS. These findings will aid in physician-
patient discussion and counseling before treatment.
Moreover, the finding that a larger hotspot leads to in-
creased LC represents an actionable metric at the time of
treatment planning, with little increase in treatment-
related morbidity. These results merit validation in
independent datasets using multiple treatment platforms or
in future prospective studies.
Conclusions
In patients with NSCLC brain metastasis treated with
single-fraction SRS, higher volume, lower isodose line, and
lower V32 were independent predictors of local failure. V32
represents a potentially actionable metric that may be altered
at the time of treatment planning to improve LC. These
results warrant further investigation in future prospective
studies.
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